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In Alzheimer disease (AD) and other tauopathies, microtubule-associated protein tau
becomes hyperphosphorylated, undergoes conformational changes, aggregates, eventu-
ally becoming neurofibrillary tangles (NFTs). As accumulating evidence suggests that NFTs
themselves may not be toxic, attention is now turning toward the role of intermediate tau
oligomers in AD pathophysiology. Sarkosyl extraction is a standard protocol for investigat-
ing insoluble tau aggregates in brains.There is a growing consensus that sarkosyl-insoluble
tau correlates with the pathological features of tauopathy.While sarkosyl-insoluble tau from
tauopathy brains has been well characterized as a pool of filamentous tau, other dimers,
multimers, and granules of tau are much less well understood. There are protocols for
identifying these tau oligomers. In this mini review, we discuss the characteristics of tau
oligomers isolated via different methods and materials.
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INTRODUCTION
Tau is a phospho-protein that belongs to the family of microtubule
(MT)-associated proteins. The primary function of tau protein is
to modulate MT dynamics for maintaining neuronal processes
and regulating axonal transport. During pathogenesis, tau protein
abnormally aggregates into intracellular, filamentous inclusions,
or neurofibrillary tangles (NFTs) in the brains of individuals
with neurodegenerative disorders. These are termed tauopathies
[reviewed in Ref. (1)].
In human tauopathies, intracellular aggregates of abnormally
hyperphosphorylated tau protein and neuronal cell loss typically
coincide within the same brain regions (2). Several transgenic
mouse models that overexpress human tau protein have demon-
strated how tau pathology and neuronal loss progresses [mouse
models are reviewed in Ref. (3)]. However, recent data suggest that
tau is involved in neuronal dysfunction before NFTs are formed
(4, 5). In vitro tau polymerization studies indicated that NFT for-
mation consists of several steps: dimerization, multimerization,
oligomerization, and protofibril formation (6–11).
About two decades ago, tau aggregation intermediates (also
referred to as AD P-tau) were isolated from the buffer-soluble
fraction derived from brains of AD patients (12). More than
10 years later, attention has focused on oligomeric tau species
in human (13) and transgenic mouse (14) brains in order to
identify the exact neurotoxic components of tau protein. How-
ever, the potential role of tau oligomers is poorly understood
because they exist in various states (e.g., dimers, multimers, and
granules). Here, we review various protocols used to isolate tau
oligomers and propose a general outline for the identification of
tau oligomers.
SOLUBLE PRE-FIBRILLAR TAU IN HUMAN AD BRAINS
Greenberg and Davies first reported to isolate sarkosyl-insoluble
tau from paired helical filament (PHF)-enriched fraction from
human AD brain homogenates (15). Cortical gray matter was
homogenized in buffer containing 10 mM Tris-HCl (pH 7.4),
1 mM EGTA, 0.8 M NaCl, and 10% sucrose, and then centrifuged
at 27,200× g. PHF-associated tau was enriched from the super-
natant by taking advantage of their insolubility in the presence
of a detergent, sarkosyl. PHF-associated tau migrated at around
57–68 kDa on one-dimensional PAGE gels. This enriched super-
natant was more acidic on two-dimensional PAGE gels compared
to extracts from normal brains. Although this PHF-associated tau
was not extracted from highly insoluble fraction containing NFTs,
the sarkosyl-insoluble tau displayed the same structural and anti-
genic properties as PHFs isolated from NFTs (16–18) and was
distinguishable from normal, soluble tau proteins.
Kopke et al. isolated non-PHF hyperphosphorylated tau from
AD brains (12). In their protocol, cortical gray matter was homog-
enized in buffer containing 20 mM Tris-HCl (pH 8.0), 0.32 M
sucrose, 10 mM β-mercaptoethanol, 5 mM EGTA, 1 mM EDTA,
5 mM MgSO4, and proteinase inhibitors. The homogenate was
then subjected to differential centrifugation, and the fraction
resulting from centrifugation between 27,000 and 200,000× g was
collected. This fraction was further extracted with 8 M urea to
separate out the PHF-enriched pool. The supernatant contained
abnormally phosphorylated non-PHF tau. These tau species were
named AD P-tau and had a molecular weight of 67–70 kDa. They
were three to fourfold more phosphorylated than tau extracted
from control brains and could be detected by Tau1 antibody
after alkaline phosphatase treatment. These highly phosphory-
lated AD P-tau proteins lost their normal MT assembly-promoting
activity, which could be recovered upon dephosphorylation with
alkaline phosphatase (19). Moreover, AD P-tau could sequester
normal tau into filamentous tau aggregates, resulting in MT
de-polymerization (20).
These studies suggest that a pool of intermediate patholog-
ical tau species exists and that this pool can be recovered in
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buffer-soluble fractions. The physiological activity and function
of these tau species is reduced compared to normal tau species due
to hyperphosphorylation. Since the intracellular mobility dynam-
ics of these intermediate tau species is much greater than that of
condensed tau aggregates in NFTs, it is possible that intermediate
tau species induce neuronal death and/or synaptic dysfunction.
Therefore, the isolation and characterization of these tau species
is paramount for understanding the pathogenesis of AD and for
searching therapeutic methods.
TAU OLIGOMERS IN MOUSE MODELS OF TAUOPATHY
The first tau transgenic mouse model of frontotemporal dementia
with Parkinsonism linked to tau on chromosome 17 (FTDP-17-
Tau) was the JNPL3 line, which overexpresses P301L mutant
4R0N tau (21). The biochemical characterization of insolu-
ble tau in these mice was done by a modified Greenberg and
Davies method (21, 22). In this protocol, mouse brains were
homogenized in buffer containing 25 mM Tris-HCl (pH 7.4),
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, phosphatase inhibitors,
and protease inhibitors. A pellet collected from 150,000× g
centrifugation was re-homogenized in high-salt/sucrose buffer
[10 mM Tris-HCl (pH 7.4), 0.8 M NaCl, 10% sucrose, 1 mM
EGTA, 1 mM PMSF] and centrifuged again at 150, 000× g.
The resulting supernatant was incubated with 1% sarkosyl,
and then centrifuged at 150, 000× g. The pellet was re-
suspended in TBS as the sarkosyl-insoluble fraction. A 64-kDa
tau predominantly existed in the sarkosyl-insoluble fraction;
this tau was phosphorylated at multiple sites. Most notably,
the amount of 64 kDa tau increased in an age-dependent man-
ner, correlating well with the pathogenesis in JNPL3 mouse
brain.
Noble et al. proposed a slightly different protocol for tissue
homogenization using RIPA buffer without SDS (23). This mod-
ification allows for the study of both cytosolic and membrane-
associated proteins involved in AD pathogenesis, such as amyloid
precursor protein (APP), in the same extracts (24).
Another broadly used tauopathy mouse model is rTg4510
mice, which express repressible P301L mutant 4R0N tau and
develop progressive age-related NFTs, neuronal loss, and behav-
ioral impairment (5). Using a protocol similar to the one for JNPL3
mice with an additional 13,000× g centrifugation as the first step,
Berger et al. identified 140 and 170 kDa multimeric tau species in
rTg4510 mouse brains (14). The 140 kDa tau was recovered in the
supernatant fraction resulting from 150,000× g centrifugation,
while the 170 kDa tau was mostly in the sarkosyl-insoluble frac-
tion. Both multimers were not affected by the presence or absence
of reducing agent, indicating that the multimers are disulfide-
bond independent. Importantly, the accumulation of 140 kDa tau
coincided with the behavioral impairments of rTg4510 mice (14).
Although this finding has had a huge impact on our understand-
ing the neurotoxic mechanisms of tau oligomers, it is still unclear
whether 140 and 170 kDa tau multimers can induce neuronal
dysfunction. This is because these multimers comprise such a
small proportion of the total tau pool (roughly< 0.1% of total
tau, as estimated by Western blot signal). It should be noted that
tau multimers with apparent molecular weights of ∼140 and
∼170 kDa are in fact tau dimers of ∼120 and ∼130 kDa, based
on Bis-Tris or Tris-acetate SDS-PAGE migration (11, 25). This was
further supported by mass spectrometry analysis of cross-linked
tau dimers (26).
Most recently, we demonstrated that TBS-extractable 64 kDa
tau species represents better the species involved in the pro-
gression of brain atrophy than does the sarkosyl-insoluble tau
species (25). These 64 kDa tau species can be recovered in the
supernatant following centrifugation of brain homogenates at
27,000× g and further separation from normal tau by 150,000× g
centrifugation. TBS-extractable 64 kDa tau and normal tau are
similar in thermo-stability but differ in other properties. Under
non-reducing gel electrophoresis conditions, nearly all 64 kDa
tau species are detected as dimers (∼130 kDa, according to size
of molecular markers), whereas most normal tau proteins are
detected as monomers. Immuno-electron microscopy revealed
that the TBS-extractable 64 kDa tau enriched fraction contains
tau-positive granules and filaments (25). This morphological
finding was supported by MC1 immunoreactivity and Ab39
insensitivity (25). The MC1 antibody recognizes an early path-
ogenic conformation of tau (27), while the Ab39 antibody only
detects mature tangles (28, 29). Overall, the characteristics of
TBS-extractable 64 kDa tau are similar to AD P-tau from human
brains.
IN VITRO TAU OLIGOMERIZATION
With tau assembly modeled in vitro, unphosphorylated recombi-
nant tau can be polymerized by inducers such as heparin, heparan
sulfate, polyunsaturated fatty acids, RNA, or quinones (30–34).
Using the heparin-induced tau self-assembly method, we pro-
duced and isolated granular-shaped tau oligomers from soluble
tau and filamentous tau by sucrose density gradient ultracentrifu-
gation (10). These granular tau oligomers were morphologically
defined by atomic force microscopy (AFM) to be 15–25 nm gran-
ules, and their molecular mass corresponded to about 40 tau
molecules (10). Once formed, granular tau can continue to form
filaments without any inducers in a concentration-dependent
manner (10).
More recently, Lasagna-Reeves et al. proposed a method to
prepare tau oligomers by using amyloid seeds (35). In their
protocol, tau oligomerization can be induced in a relatively
short period (1 h incubation at room temperature) after adding
Aβ42 oligomers. After a total of three rounds of seeding pro-
cedures, Aβ42 seeds could be diluted to below the detection
limit (35). Examination of these tau oligomers by transmission
electron microscopy or AFM revealed a spherical morphology
(35). This unique method of producing tau oligomers is a rea-
sonable representative model supporting the amyloid hypoth-
esis (36, 37), in which Aβ oligomers trigger NFT formation.
Interestingly, tau oligomers, but not tau monomers or tau fib-
rils, can cause memory impairment in wild-type mice (13)
and can decrease long-term potentiation in hippocampal brain
slices (38).
The production of granular tau oligomers must be initi-
ated by dimerization of tau monomers. Heparin-induced tau
polymerization allows us to detect initial dimers because of the
Frontiers in Neurology | Neurodegeneration July 2013 | Volume 4 | Article 102 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ren and Sahara Characteristics of tau oligomers
relatively slower kinetics compared to arachidonic acid-induced
tau polymerization (6, 39). It begins by increasing the formation
of cysteine-dependent dimers, which occur prior to the detec-
tion of thioflavin T (ThT) binding (11). The kinetics of tau
polymerization is dependent on oxidative/reducing state. Higher-
order oligomers and aggregates assemble more rapidly in the
absence of the reducing agent dithiothreitol (DTT) (11). However,
cysless-tau (4R tau with both C291A and C322A mutations) forms
dimers, which eventually aggregate into fibrils after 24 h incuba-
tion with heparin, suggesting that tau aggregation occurs without
disulfide-bond formation (11).
Two distinct tau dimers (i.e., cysteine-dependent and cysteine-
independent dimers) have been identified in tauopathy mouse
models, including JNPL3 mice (11) and rTg4510 mice (14, 25).
These dimers have also been shown in cell cultures (11, 40).
Dimer formation is an essential step for their further assembly
into higher-order oligomers. Although these dimers themselves
may not exist in a steady state, it is important to detect the initial
step of tau dimerization.
GENERATION OF TAU OLIGOMER-SPECIFIC ANTIBODIES
A monoclonal antibody that selectively recognizes tau dimers
and higher-order oligomers has been generated by Binder’s
group (26). This antibody, named tau oligomeric com-
plex 1 (TOC1), was made against benzophenone-4-maleimide
cross-linked recombinant tau dimers (26). Immunogold label-
ing and dot-blot analysis of aggregated recombinant tau revealed
that TOC1 selectively labels tau dimers or oligomers but not fil-
aments (26). Based on their preliminary mapping of the TOC1
epitope, the proline-rich region (Gly155-Gln244) and the C-
terminal portion (Leu376-Ser421) were identified as potential
binding segments for forming cross-linked tau dimer (26). Since
these two regions are on the opposite sides of the MT-binding
domains, Patterson et al. advanced the idea of the formation of an
antiparallel dimer (26).
TOC1 immunoreactivity is selectively detectable in the early
stage of AD pathogenesis; however, TOC1 antibody fails to
label mature tangles in AD brains (26). In rTg4510 mice,
TOC1 immunoreactivity was observed in the TBS-extractable
64 kDa tau enriched fraction and linked to early pathological
changes (Sahara, in preparation). Notably, the immunohisto-
chemical staining pattern of TOC1 antibody was clearly dif-
ferent from those of MC1 and Ab39 antibodies (Figure 1).
Since NFTs themselves might be protective [reviewed in Ref.
(41)], other harmful tau species such as tau oligomers are
currently of particular interest. If TOC1 antibody selectively
interacts with tau dimers and higher-order oligomers but not
tau filaments, and if those species cause neurotoxicity, this
antibody can be a useful tool to track the pathway of tau
neurotoxicity.
FIGURE 1 | Light microscopic images of immunostained brain sections
from a non-transgenic mouse, a rTg4510 mouse, and human with AD.
Formalin-fixed paraffin sections were stained with TOC1 (1:2500), MC1
(1:1000), and Ab39 (1:250) antibodies by the Dako Universal Autostainer
(Dako, Carpinteria, CA, USA). The sections were then counterstained with
hematoxylin. TOC1 diffusely stained cytoplasmic regions of neurons (top
panels, rTg4510 and AD brains), while MC1 and Ab39 densely stained these
neurons (middle and bottom panels, respectively). This difference in staining
pattern is due to the specific binding of TOC1 antibody to premature tau
aggregates. Scale Bar, 100µm.
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Table 1 | Summary of brain-derived tau oligomer preparation methods.
Product Reference Material origin Detect method Oligomer properties
AD P-tau Kopke et al. (12), Alonso
et al. (20), Alonso et al.
(44)
AD patients WB, EM AD P-tau is isolated from the 27 K–200 K×g fraction,
soluble in urea, hyperphosphorylated, no ubiquitin
immunoreactivity, self-assembly into filaments,
sequesters N-tau
140 and 170 kDa
tau
Berger et al. (14) rTg4510 mice
JNPL3 mice
WB, SEC Disulfide-bond independent, correlates with memory
loss, 140 kDa tau is not hyperphosphorylated, 170 kDa
tau is hyperphosphorylated, and has strong
immunoreactivity with AT8
TBS-extractable
64 kDa tau
Sahara et al. (25) rTg4510 mice WB, IHC, EM TBS-extractable 64 kDa tau is isolated from 27 K to
150 K×g fraction, thermo-stable, hyperphosphorylated,
mostly disulfide-bond-dependent, correlates with brain
atrophy, contains tau-positive granules/short filaments
T22-positive tau Lasagna-Reeves et al.
(38), Lasagna-Reeves et
al. (42)
AD patients WB, IHC, SEC,
AFM
Hyperphosphorylated, not ubiquitinated at pretangle
stage, contains oligomers with 4–8 nm diameters,
propagate abnormal tau conformation of endogenous
murine tau
WB, Western blot; EM, electronic microscopy; IHC, immunohistochemistry; SEC, size-exclusion chromatography; AFM, atomic force microscopy.
Another tau oligomer-specific antibody, T22, was generated
by Kayed’s group (42) against antigenic tau prepared from Aβ
seeding of tau oligomers (35). The specificity of this anti-
body was confirmed by ELISA and dot blotting. It detects
only tau oligomers but not tau monomers or PHF fibrils pre-
pared by the heparin-induced tau polymerization method (42).
Immunohistochemically, this antibody selectively stains pretan-
gles, neuritic plaques, and neuropil threads but not ghost tan-
gles in AD brain sections (42). Western blotting showed that
T22 antibody recognizes higher-molecular-weight tau species
(e.g., dimers, trimers, and tetramers) but not monomers (42).
It should be noted that the SDS-PAGE samples were not dena-
tured by boiling before running on gels and that T22 immunore-
activity was diminished by denaturing agents such as 8 M
urea (42).
These novel tau oligomer-specific antibodies provide a new
method to diagnose the early pathological changes that occur
in tauopathy. It would be extremely useful to develop methods
employing cerebrospinal fluid biomarkers combined with total
tau, phosphorylated tau, tau oligomers, and other biomarker mea-
surements to differentially diagnose dementias, such as AD, fron-
totemporal lobar degeneration, progressive supranuclear palsy,
corticobasal degeneration, dementia with Lewy bodies, vascular
dementia, and prion disease.
CONCLUSION
Abnormal tau aggregation is considered to be a critical patho-
logical feature of tauopathy. However, the initial molecular event
of tau pathogenesis is yet unclear. The hyperphosphorylation of
tau is strongly suggested to be directly correlated with the sever-
ity of AD pathology (43). Iqbal and colleagues demonstrated
that hyperphosphorylated tau extracted from AD brain reduces
MT stabilization, sequesters normal tau from MT, and aggregates
themselves in the absence of inducer molecules (20, 44). Many
studies attempting to identify tau oligomers have demonstrated
the existence of hyperphosphorylated tau oligomers in human
and transgenic mouse brains (e.g., AD P-tau, 140 and 170 kDa
tau multimers, TBS-extractable 64 kDa tau, and T22 antibody-
positive tau oligomers) (Table 1). Thus, hyperphosphorylation of
tau could be the initial event of NFT formation. However, the
amount of 140 kDa tau multimer (normal tau dimer) correlates
well with behavioral deficits (14), suggesting that hyperphospho-
rylated tau oligomers may not be essential for neurotoxicity. If
antibodies can be generated to recognize non-phosphorylated
and hyperphosphorylated tau dimers independently, we will be
able to better identify toxic tau species and optimize potential
oligomerization inhibitors as possible novel therapies. Standard-
ized isolation methods of tau oligomers are in need to improve
consistency between researchers.
In summary, accumulating evidence from biochemistry,
immunology, and molecular imaging reveal the existence of tau
oligomers as mainly buffer-soluble, non-filamentous, granular-
shaped conformers. The neurotoxicity of these oligomers has been
confirmed in both in vitro and in vivo experiments (4, 5, 14, 42, 45).
The next step of tau oligomer research should investigate whether
tau dimers and/or non-granular oligomers exist and functionally
correspond to neuronal dysfunction.
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